Therapeutic response to prednisone in relation to age in polymyalgia rheumatica: a comparison study

[1]  E. Matteson,et al.  Epidemiology of Polymyalgia Rheumatica 2000–2014 and Examination of Incidence and Survival Trends Over 45 Years: A Population‐Based Study , 2017, Arthritis care & research.

[2]  F. Berenbaum,et al.  Effect of age at rheumatoid arthritis onset on clinical, radiographic, and functional outcomes: The ESPOIR cohort. , 2016, Joint, bone, spine : revue du rhumatisme.

[3]  S. Hider,et al.  Characterising those with incident polymyalgia rheumatica in primary care: results from the PMR Cohort Study , 2016, Arthritis Research & Therapy.

[4]  H. Boulahdour,et al.  Utility of 18F-fluoro-dexoxyglucose positron emission tomography for the diagnosis of polymyalgia rheumatica: a controlled study. , 2016, Rheumatology.

[5]  A. Saraux,et al.  Efficacy of first-line tocilizumab therapy in early polymyalgia rheumatica: a prospective longitudinal study , 2016, Annals of the rheumatic diseases.

[6]  K. Barraclough,et al.  2015 Recommendations for the Management of Polymyalgia Rheumatica: A European League Against Rheumatism/American College of Rheumatology Collaborative Initiative , 2015, Arthritis & rheumatology.

[7]  P. Emery,et al.  Whole-body MRI of patients with polymyalgia rheumatica identifies a distinct subset with complete patient-reported response to glucocorticoids , 2015, Annals of the rheumatic diseases.

[8]  E. Matteson,et al.  Current evidence for therapeutic interventions and prognostic factors in polymyalgia rheumatica: a systematic literature review informing the 2015 European League Against Rheumatism/American College of Rheumatology recommendations for the management of polymyalgia rheumatica , 2015, Annals of the rheumatic diseases.

[9]  S. Mori,et al.  Glucocorticoid-resistant polymyalgia rheumatica: pretreatment characteristics and tocilizumab therapy , 2014, Clinical Rheumatology.

[10]  K. Warrington,et al.  Polymyalgia rheumatica , 2013, The Lancet.

[11]  M. Brown,et al.  Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1) , 2012, Annals of the rheumatic diseases.

[12]  A. Iagnocco,et al.  2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative , 2012, Annals of the rheumatic diseases.

[13]  C. Kao,et al.  Impact of age on FDG uptake in the liver on PET scan. , 2010, Clinical imaging.

[14]  C. Bombardier,et al.  Predictors for remission in rheumatoid arthritis patients: A systematic review , 2010, Arthritis care & research.

[15]  D. Lawlor,et al.  Secondhand smoke (SHS) exposure is associated with circulating markers of inflammation and endothelial function in adult men and women , 2010, Atherosclerosis.

[16]  S. Mori,et al.  Clinical characteristics of polymyalgia rheumatica in Japanese patients: evidence of synovitis and extracapsular inflammatory changes by fat suppression magnetic resonance imaging , 2007, Modern rheumatology.

[17]  A. Radjenovic,et al.  Evidence for a different anatomic basis for joint disease localization in polymyalgia rheumatica in comparison with rheumatoid arthritis. , 2007, Arthritis and rheumatism.

[18]  V. Treyer,et al.  F-18 FDG Whole-Body PET for the Assessment of Disease Activity in Patients With Rheumatoid Arthritis , 2006, Clinical nuclear medicine.

[19]  J. Braun,et al.  Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor α blockers in ankylosing spondylitis , 2004, Annals of the rheumatic diseases.

[20]  G. Kersley.  European League Against Rheumatism , 1951 .

[21]  Kari C. Nadeau,et al.  in a prospective longitudinal study , 2020 .